# BPC-157 TB-500: The Wolverine Research Blend, Status First > BPC-157 TB-500 is the two-peptide "Wolverine" tissue-repair blend — a 15-residue body-protection compound paired with the Ac-LKKTETQ actin fragment. A distilled, cited field-record, regulatory status set first. Two distinct peptides mounted as two specimens — a 15-residue body-protection compound beside a 7-residue actin-binding fragment. This is what the published record on each establishes, with its regulatory and compounded-access status read first. ## What the Wolverine blend is, set down plainly BPC-157 TB-500 is a two-peptide pairing the research community calls the "Wolverine" blend, discussed as a tissue-repair stack. It is two synthetic peptides mounted side by side — not a single molecule, not an approved medicine, and not a co-formulation with a validated composition. Each specimen carries its own paper trail, and the most consequential facts about the pairing are regulatory, which is why this site sets the [Wolverine legal status and 503A category](/legal-status) before anything else. The first specimen is BPC-157 — Body Protection Compound 157 — a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, molecular weight roughly 1,419.5 Da) derived from a partial sequence of a protein found in human gastric juice [1]. The second is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, roughly 889.0 Da) corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4 [8]. That second provenance carries a caveat worth pinning to the page early. The "TB-500" sold and stacked is the seven-residue fragment, but the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4,963 Da), not the 7-mer [4]. The blend inherits that gap: it leans on full-protein data for one of its two legs. Everything that follows is a digest of the published record — a labeled specimen plate, not a protocol, not a recommendation, and not a claim about the combination the literature has not made. ## BPC-157 and TB-500: What the Wolverine Blend Pairs BPC-157 and TB-500 are paired because they are described as acting through complementary but largely non-overlapping pathways — which is both the basis of the "synergy" claim and its limit [4]. BPC-157 supplies the cytoprotective, pro-angiogenic leg. In preclinical models it up-regulates VEGFR2 and promotes its internalization, driving the VEGFR2-Akt-eNOS pathway and modulating the nitric-oxide system [2]. In a fully transected rat Achilles tendon it improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, dosed at 10 µg/kg or 10 ng/kg intraperitoneally [1]. TB-500 supplies the cytoskeletal leg. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating the actin dynamics that drive cell migration [3]. Thymosin Beta-4 — the parent protein — binds actin, mobilizes cells, decreases myofibroblast number, limits inflammation after injury, and promotes angiogenesis [4]. The details sit on the research page; the pharmacokinetic record, including [BPC-157 and TB-500 half-life](/half-life), sits on its own plate. The honest center of the pairing is what is missing: no controlled study has defined a combined dose, ratio, or endpoint for the two given together [9]. ### What Is the Wolverine Peptide Blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or molecular weight of its own, and is not an approved product. Commercial vials carry a combined per-vial mass — for example, 10 mg + 10 mg — but no standardized ratio is clinically validated [4]. ### What Are BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein — the cytoprotective and angiogenic component [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 — the cytoskeletal, cell-migration component [3][8]. The blend pairs the two as a tissue-repair stack. ## What the record studies the blend for In animal models, the two constituents have been studied separately for tendon, ligament, muscle, and wound repair and for angiogenesis [1][2][4]. BPC-157 carries the most-cited tissue-repair result — accelerated healing of a transected rat Achilles tendon [1] — and the clearest mechanistic arm, VEGFR2-driven angiogenesis [2]. TB-500's parent protein carries a settled actin-binding structure and a consolidated regenerative profile [3][4]. That distinction — strong single-compound animal work on one side, an unstudied pairing on the other — runs through every page here. ### What Is the BPC-157 and TB-500 Blend Studied For? In animal models, the two constituents have been studied separately for tendon, ligament, muscle, and wound repair and for angiogenesis [1][2][4]. The blend itself has no controlled human efficacy data; combined use is investigational. The reported uses are single-compound and preclinical, and for most of the "TB-500" data are drawn from full-length thymosin beta-4 rather than the marketed 7-mer [4]. ### What Is the Difference Between BPC-157 and TB-500? They are two different peptides with two different jobs. BPC-157 is a 15-residue pentadecapeptide from a gastric-juice protein, acting as a cytoprotective and angiogenic signal through VEGFR2-Akt-eNOS [1][2]. TB-500 is a 7-residue acetylated fragment of Thymosin Beta-4, acting as a cytoskeletal actin-sequestration signal [3]. They are structurally unrelated, with distinct mechanisms; one signals vessels and tissue protection, the other the cytoskeleton [4]. ## The BPC-157 TB-500 Stack: Why the Research Community Pairs Them The BPC-157 TB-500 stack is built on mechanistic complementarity. The pairing rationale is that BPC-157 supplies a local cytoprotective and pro-angiogenic signal while TB-500 supplies a cytoskeletal cell-migration signal, on the theory that two repair levers add up to more than either alone [4]. The honest framing matters. This is a theoretical extrapolation from each peptide's independently characterized mechanism — not a finding from a controlled combination study. A 2025 systematic review of BPC-157 in orthopaedic sports medicine, covering 36 studies with only one human among them, makes no mention of TB-500 or any combination [9]. The marketing language around "Wolverine" — rapid healing of any injury, performance enhancement — outruns a published evidence base that is preclinical, single-compound, and largely from animal models [11]. Because the blend has no validated quantitative profile of its own, the numbers on this site are constituent-level and labeled as such. Read each against its source through the [frequently asked questions](/faq), and weigh the access status as the first fact, not the last. --- A distilled field-record of the BPC-157 and TB-500 literature — each peptide pressed as its own cited specimen, its 503A access status read first, with no clinic behind the folio and nothing here prescribed or sold.